

Nucleotide-Deduced Amino Acid Sequence, Isolation, and Purification of Heat Shock Chlamydial Proteins

Morrison, R.B., Caldwell, H.D. (NIAID)
Filed 25 Feb 92

Serial No. 07/841,323 (DIV of 07/
679,302, DIV of USPN 5,071,962)
Licensing Contact: Carol Lavrich (301/
496-7735 ext 287)

The chlamydial heat shock protein (HSP60) is an immunodominant genus common antigen which has been implicated in immunopathologic delayed type hypersensitivity reactions during chlamydial infections. The HypB gene which encodes the chlamydial HSP60 has been cloned and characterized. High levels of HSP60 expression have been obtained in prokaryotic vectors and methods have been developed for the purification of the chlamydial HSP60 protein. Availability of large quantities of purified recombinant chlamydial HSP60 offers novel approaches to preventing, treating, and diagnosing chlamydial infections of humans. [portfolio: Infectious Diseases—Diagnostics, bacterial]

Methods and Compositions for Diagnosing Cat Scratch Disease and Bacillary Angiomatosis

Regnery, R.L., Anderson, B.E. (CDC)
Serial No. 07/822,539
Patent Issued 21 Mar 95
U.S. Patent No. 5,399,485
Licensing Contact: Carol Lavrich (301/
496-7735 ext 287)

A previously unidentified pathogenic species of the rickettsia-like *Bartonella*, named *B. henselae*, sp. nov., has been identified and characterized. (Note: The genus designation *Bartonella* is now applied to and replaces the *Rochalimaea* genus designation.) This new organism causes two clinically related diseases: Bacillary angiomatosis and cat scratch disease. Currently, diagnosis of *Bartonella* diseases is limited to detection of the etiologic agent associated with "trench fever", referred to as *B. quintata*. Novel diagnostic tests using immunofluorescence assays or ELISAs can detect the newly discovered pathogen in sera from infected individuals and distinguish it from *B. quintata*, thus offering improved differential diagnosis for disease syndromes such as "trench fever", bacillary angiomatosis, cat scratch disease, and bacillary peliosis hepatitis. [portfolio: Infectious Diseases—Diagnostics, bacterial]

Effect of Cadmium on Human Ovarian Cancer Cells With Cisplatin Resistance

Bo Lee, K., Parker, R.J., Reed, E. (NCI)

Filed 3 Mar 95
Serial No. 08/398,460
Licensing Contact: Raphe Kantor (301/
496-7735 ext 247)

The present invention describes Cadmium (Cd) as a potential anticarcinogenic compound useful in treating ovarian cancer. The inventors observed strong tumor suppressive effects when applied to human ovarian cancer cell lines *in vitro*. The effects of Cd on cellular sensitivity, cellular drug accumulation and efflux, and Cd-DNA adduct formation and repair were examined. Cadmium is shown to have a subcellular profile that is similar, though not identical, to cisplatin, suggesting the possibility of future use of Cd as an anti-cancer agent. [portfolio: Cancer—Therapeutics, conventional chemotherapy, antimetabolites]

Trapping of Aflatoxins and Phytoestrogens

Umrigar, P.P., Kuan, S.S. (FDA)
Filed 6 Jan 93
Serial No. 08/001,573
Licensing Contact: John Fahner-Vihtelic
(301/496-7735 ext 285)

A unique process has been invented for removing aflatoxins and phytoestrogens from food samples that is a significant improvement over currently available methods. Aflatoxins are carcinogenic substances that are found in foods such as grains and peanuts and, thus, are a danger to public health. Phytoestrogens—structurally related to aflatoxins—are found in soy products and also are of concern to public health. Therefore, it is important to be able to measure concentrations of these compounds in foodstuffs. The current method for determining aflatoxin or phytoestrogen concentrations in foods requires passing a food sample through an affinity column containing immobilized antibodies specific for aflatoxins or a solid phase extraction (SPE) column for phytoestrogens. The bound aflatoxins or phytoestrogens are eluted from the affinity column and then measured using high performance liquid chromatography; however, such affinity columns and SPE columns are extremely expensive, have limited shelf life, and cannot be reused. These limitations have been overcome by developing columns packed with new derivatives of a copolymer of cyclodextrin and epichlorohydrin. These new copolymers, which have proven particularly useful in trapping aflatoxins and phyto-estrogens, are extremely stable and are not damaged when aflatoxins or phytoestrogens are removed by a suitable solvent. Thus,

these materials are re-usable. [portfolio: Devices/Instrumentation—Miscellaneous]

Dated: May 1, 1995.

Barbara M. McGarey,
Deputy Director, Office of Technology
Transfer.

[FR Doc. 95-11422 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-P

National Institute on Alcohol Abuse and Alcoholism; Meetings

Pursuant to Public Law 92-463, notice is hereby given of meetings of the National Institute on Alcohol Abuse and Alcoholism.

The National Advisory Council on Alcohol Abuse and Alcoholism meeting on June 1 will be open to the public, as noted below, to discuss Institute programs and other issues relating to committee activities as indicated in the notice. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ida Nestorio at 301-443-4375.

The following meetings will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6) of Title 5, U.S.C. and section 10(d) of Public Law 92-463, for the review, discussion and evaluation of individual research grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of the meetings and the rosters of committee members may be obtained from: Ms. Ida Nestorio, Office of Scientific Affairs, National Institute on Alcohol Abuse and Alcoholism, Willco Building, Suite 409, 6000 Executive Blvd., Rockville, MD 20892-7003, Telephone: 301-443-4375. Other information pertaining to the meetings can be obtained from the contact person indicated.

Name of Committee: National Advisory Council on Alcohol Abuse and Alcoholism.

Executive Secretary: James F. Vaughan, 6000 Executive Blvd., Suite 409, Bethesda, MD 20892-7003, 301-443-4375.

Dates of Meeting: June 1, 1995.

Place of Meeting: Delegate Room D, Building 45 (Natcher), NIH Campus, 9000 Rockville Pike, Bethesda, MD 20892.

Open: June 1, 10:30 a.m. to adjournment.

Agenda: Discussion of Institute extramural research programs, health services research, and other program and peer review issues relevant to Council activities.

Closed: June 1, 8 a.m. to 10:30 a.m.

Agenda: To review and evaluate grant applications.

The following review committee meetings will be totally closed.

Name of Committee: Neuroscience and Behavior Subcommittee of the Alcohol Biomedical Research Review Committee.

Dates of Meeting: June 5–7, 1995.

Time: 9 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Antonio Noronha, Ph.D., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–9419.

Agenda: To review and evaluate grant applications.

Name of Committee: Clinical and Treatment Subcommittee of the Alcohol Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Elsie D. Taylor, Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–9787.

Agenda: To review and evaluate grant applications.

Name of Committee: Epidemiology and Prevention Subcommittee of the Alcohol Psychosocial Research Review Committee.

Dates of Meeting: June 8–9, 1995.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn, 480 King Street, Alexandria, VA.

Contact Person: Thomas D. Sevy, M.S.W., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–6106.

Agenda: To review and evaluate grant applications.

Name of Committee: Biochemistry, Physiology, and Medicine Subcommittee of the Alcohol Biomedical Research Review Committee.

Dates of Meeting: June 15–17, 1995.

Place of Meeting: Double Tree Hotel, Denver, CO.

Time: 9 a.m. to adjournment.

Contact Person: Ronald Suddendorf, Ph.D., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–2932.

Agenda: To review and evaluate grant applications.

(Catalog of Federal Domestic Assistance Program No. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.281, Scientist Development Award, Research Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.891, Alcohol Research Center Grants; National Institutes of Health).

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–11421 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and Musculoskeletal and Skin Disease; Notice of Meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council to provide advice to the National Institute of Arthritis and Musculoskeletal and Skin Diseases on June 1 and 2, 1995, Conference Room 6, Building 31, National Institutes of Health, Bethesda, Maryland.

The meeting will be open to the public June 1 from 8:30 a.m. to 9 a.m. to discuss administrative details relating to Council business and special reports. Attendance by the public will be limited to space available.

The meeting of the Advisory Council will be closed to the public on June 1 from 9 a.m. to approximately 5 p.m. and if necessary the closed portion will continue on June 2 from 8:30 a.m. to adjournment in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92–463, for the review, discussion and evaluation of individual grant applications. These deliberations could reveal confidential trade secrets or commercial property, such as patentable materials, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Tommy Broadwater, Executive Secretary, National Arthritis and Musculoskeletal and Skin Diseases Advisory Council, NIAMS, Natcher Building, Room 5AS–13, Bethesda, Maryland 20892, (301) 594–2463.

A summary of the meeting and roster of the members may be obtained from the Extramural Programs Office, NIAMS, Natcher Bldg., Rm. 5AS–13, National Institutes of Health, Bethesda, Maryland 20892, (301) 594–2463.

(Catalog of Federal Domestic Assistance Program No. 93.846, Arthritis, Bone and Skin Diseases, National Institutes of Health)

Dated: May 3, 1995.

Susan K. Feldman,

NIH Committee Management Officer.

[FR Doc. 95–11419 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Heart Attack Alert Program Coordinating Committee, sponsored by the National Heart, Lung, and Blood Institute on June 13, 1995, from 8:30 a.m. to 3:15 p.m., at the Bethesda Holiday Inn Hotel, 8120 Wisconsin Avenue, Bethesda, Maryland 20814, (301) 652–2000.

The entire meeting is open to the public. The Coordinating Committee is meeting to discuss the progress of the National Heart Attack Alert Program with its participating organizations. Attendance by the public will be limited to space available.

For the detailed program information, agenda, list of participants, and meeting summary, contact: Ms. Mary McDonald Hand, Coordinator, National Heart Attack Alert Program, Office of Prevention, Education and Control, National Heart, Lung, and Blood Institute, National Institutes of Health, 31 Center Drive MSC 2480, Bethesda, Maryland 20892–2480, (301) 496–1051.

Dated: May 3, 1995.

Claude Lenfant,

Director, NHLBI.

[FR Doc. 95–11425 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose

To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: June 5, 1995.

Time: 2 p.m.

Place: Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis D. Artis, Grant Technical Assistant, Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–6470.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: June 6, 1995.

Time: 12:30 p.m.

Place: Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.